Patent · US Active

HCV entry factor, Occludin

US8940960B2 · kind B2 · utility

0Cited by

3References

2Claims

0Family size

Assignee

The Rockefeller University · US

Inventors

Alexander Ploss · Princeton, US
Matthew Evans · Shrewsbury, US
Charles Rice · New York, US

Key dates

Filing date	Oct 1, 2009
Grant date	Jan 27, 2015
Priority date	—
Expiry date	Jul 31, 2030

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/00
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV-susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.